<div id="readability-page-1">Novavax, Inc. (NASDAQ:NVAX) ranks among the most oversold biotech stocks to invest in. Novavax, Inc. (NASDAQ:NVAX) announced its third-quarter 2025 financial results on November 6, emphasizing the company’s continuous strategic shift from a direct COVID-19 commercial operation to an R&amp;D-focused company, especially in partnership with Sanofi. For the third quarter, Novavax, Inc. (NASDAQ:NVAX) reported total […]</div>

諾瓦瓦克斯醫藥

<p>諾瓦瓦克斯醫藥（NASDAQ:NVAX）公佈了 2025 年第三季度財務業績，強調了從 COVID-19 銷售轉向專注於研發的戰略轉變，特別是與賽諾菲的合作。該公司被認為是最被低估的生物科技股票之一，值得投資</p>

諾瓦瓦克斯從新冠疫苗銷售轉向研發重點，並更新了 2025 年的預測